News & Updates
Filter by Specialty:
What is the most preferred first-line agent for paediatric alopecia areata?
25 May 2022
byStephen Padilla
In the treatment of paediatric alopecia areata (AA), an autoimmune, nonscarring hair loss disorder with a variable disease course and significant psychosocial impact, the most preferred first-line agent is topical corticosteroids, followed by contact immunotherapy, according to a study.
What is the most preferred first-line agent for paediatric alopecia areata?
25 May 2022
Upadacitinib provides robust, long-term control of moderate-to-severe AD
23 May 2022
byAudrey Abella
Follow-up data from two replicate ongoing phase III trials – Measure Up 1 and Measure Up 2 – demonstrated favourable longer-term benefit-risk profile of upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis (AD).
Upadacitinib provides robust, long-term control of moderate-to-severe AD
23 May 2022
Lirentelimab shows promise in treatment-resistant chronic urticaria
14 May 2022
In patients who suffer from antihistamine-resistant chronic urticaria (CU), lirentelimab seems to be effective at controlling the disease and reducing disease activity, reports a recent study.